C4 Therapeutics Inc [CCCC] stock is trading at $4.09, up 4.34%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CCCC shares have gain 7.92% over the last week, with a monthly amount glided 4.60%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
C4 Therapeutics Inc [NASDAQ: CCCC] stock has seen the most recent analyst activity on December 19, 2024, when Wells Fargo upgraded its rating to a Overweight and also boosted its price target to $12 from $8. Previously, Stephens started tracking the stock with Equal-Weight rating on November 18, 2024, and set its price target to $4. On January 29, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $6 on the stock. Stifel upgraded its rating to a Buy and increased its price target to $12 on December 13, 2023. Credit Suisse upgraded its rating to a Neutral and reduced its price target to $10 on February 24, 2023. JP Morgan downgraded its rating to Underweight for this stock on February 24, 2023, and downed its price target to $5. In a note dated November 04, 2022, JP Morgan downgraded an Neutral rating on this stock and revised its target price from $22 to $15.
C4 Therapeutics Inc [CCCC] stock has fluctuated between $3.43 and $11.88 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. C4 Therapeutics Inc [NASDAQ: CCCC] shares were valued at $4.09 at the most recent close of the market. An investor can expect a potential return of 291.2% based on the average CCCC price forecast.
Analyzing the CCCC fundamentals
C4 Therapeutics Inc [NASDAQ:CCCC] reported sales of 33.67M for the trailing twelve months, which represents a growth of 38.75%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -3.54%, Pretax Profit Margin comes in at -3.13%, and Net Profit Margin reading is -3.13%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.42 and Total Capital is -0.36. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.91 points at the first support level, and at 3.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.27, and for the 2nd resistance point, it is at 4.44.
Ratios To Look Out For
For context, C4 Therapeutics Inc’s Current Ratio is 6.31. Further, the Quick Ratio stands at 6.31, while the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 9.18, the price to book ratio is 1.19.
Transactions by insiders
Recent insider trading involved Salter Malcolm, Director, that happened on Nov 18 ’24 when 13000.0 shares were purchased. Director, Salter Malcolm completed a deal on Oct 18 ’24 to buy 13000.0 shares. Meanwhile, Director Salter Malcolm bought 8561.0 shares on Oct 11 ’24.
